ROE
9.1%
ROE 9.1% is below the quality threshold; compare the multi-year trend before calling it structural.
NYSE · Healthcare · Large Cap · Mkt cap $181.3B · Vol 5.79M
$104.71
▼ -5.21% today
Live · market · updated 10:06:03 PM
Day $104.59–$108.18 · 52w $81.97–$132.03
Research Abbott Laboratories (NYSE: ABT) using available valuation, profitability and leverage data. Check each figure's source and compare reporting periods before drawing conclusions. Missing provider data must not be treated as a reported company fact.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Source: Yahoo Finance — Abbott Laboratories company profileCompany website
Available ratios are snapshots. This page does not provide a complete historical quarterly-results, profit-and-loss, balance-sheet or shareholding series. Use company filings to verify reporting periods, accounting changes and trends.
Weighted 13-factor score / 100
Abbott Laboratories scores 56/100 on the DeepScreen quality-and-value model. Growth is running near 14.5% with a PEG of 1.54, ROCE of 6.6% and debt/equity at 0.61x. Quality and price roughly offset each other; wait for a better entry or clearer growth.
Vision & Utility score and Secret Tips badges is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Target price, trim level & stop-loss is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
The 56/100 score is a weighted average of 13 fundamental factors. This panel shows which factor scores contribute most to the current model result.
Good upside gearing. Weighted contribution: 4.7 points.
Typical for the sector. Weighted contribution: 6.0 points.
Typical for the sector. Weighted contribution: 5.0 points.
Manageable. Weighted contribution: 7.1 points.
Low for the sector. Weighted contribution: 0.4 points.
Below cost of capital risk. Weighted contribution: 1.0 points.
Weak. Weighted contribution: 2.1 points.
High payout, little left to reinvest. Weighted contribution: 1.4 points.
Factor scores are model outputs, not forecasts. A high or low factor score describes how that metric is treated by the DeepScreen rules; review the underlying value and its source before drawing a broader conclusion.
Current operating, capital-efficiency and cash-flow metrics using the latest available provider data.
Provider-reported period-over-period growth
Provider-reported period-over-period growth
Return on equity
Return on capital employed
Net income as a share of revenue
Debt relative to shareholder equity
69% of operating cash flow
Cash $4.30B · Debt $31.44B
Provider periods can differ by field. Growth figures are presented as reported by the upstream provider; they are not reconstructed from an expensive historical time series.
Threshold-based research checks from the latest available fundamentals. These are on-page signals, not push notifications or predictions.
Operating Leverage: 2.44x — good upside gearing
Signals are intended to highlight questions for research, not replace company filings or independent review.
Industry match: Medical Devices. Peers use the same regional market universe, same sector, provider-reported industry where available, and market-cap proximity.
Peer fundamentals are still loading. The comparison will populate automatically when comparable company data arrives.
DeepScreen Secret Tips, traps & X-Ray analysis is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Accounting quality and solvency screens. Anything that can't be computed from available filings data is left blank rather than estimated.
Piotroski F-Score
6/86
6 of 8 financial-health checks passed (1 checks need data this provider doesn't publish).
Altman Z-Score
Insufficient data—
Needs total assets, operating profit and debt — not published for this listing yet.
Beneish (earnings quality)
Low distortion risk1.89
Accrual-quality check only: operating cash flow is 189% of reported net profit. Below 80% means profits aren't fully backed by cash.
Scores are free. The criteria-by-criteria breakdown — exactly which checks this company failed — is part of DeepScreen Pro.
P/E Ratio (TTM)
Live39.1x
Fairly priced
Price divided by earnings per share: how much you pay today for ₹1/$1 of annual profit. Only compare within the same industry.
PEG Ratio
LivePro
Advanced ratio · DeepScreen Pro
Pro
P/S Ratio
Live3.76x
Moderate
Price relative to revenue. Sales are much harder to accounting-fudge than earnings, so this is a trustworthy number — and it's often the only usable multiple for loss-making or early-stage companies where P/E doesn't exist. But revenue without margin means nothing on its own: always read it alongside net margin.
P/B Ratio
Live3.55x
Typical for the sector
Price versus net asset value. Asset-light businesses like this one carry most of their value in people and IP, not machinery or property, so P/B runs structurally high here — not a red flag by itself. Weigh P/E and ROE more heavily instead.
EV/Revenue
LivePro
Advanced ratio · DeepScreen Pro
Pro
EV/EBITDA
LivePro
Advanced ratio · DeepScreen Pro
Pro
ROE
Live9.1%
Weak
Return on shareholder equity. High ROE is great — unless it is manufactured by heavy debt, so always read it next to ROA and D/E: high ROE with low ROA is the classic debt-trap pattern.
ROA
Live4.9%
Low for the sector
Net Income / Total Assets — how efficiently the whole business converts its asset base into profit. Computed as ROE / (1 + D/E) when live data is unavailable. Only compare within the same industry: asset-light businesses (IT, services) will always show a structurally higher ROA than asset-heavy ones (steel, airlines, utilities) simply because they carry far less on the balance sheet to begin with, not because they're better run.
ROCE
Modeled6.6%
Below cost of capital risk
Return on all capital employed (equity plus debt). The cleanest quality signal because debt cannot flatter it.
Debt / Equity
Live0.61x
Manageable
Total liabilities divided by shareholders' equity — the broadest leverage measure. High leverage boosts ROE in good years and destroys it in bad ones.
LT Debt / Equity
ModeledPro
Advanced ratio · DeepScreen Pro
Pro
Payout Ratio
Live93%
High payout, little left to reinvest
Share of profit paid out as dividend. Above 100% means the company is funding the dividend from debt or reserves, not profit — a genuine red flag, not just 'high'. 30–60% is the classic sustainable balance; well below that usually just means a growth company reinvesting rather than anything wrong.
Operating Leverage
Modeled2.44x
Good upside gearing
How much profit jumps for each 1% of extra sales — driven by how much of the cost base is fixed (rent, salaries) versus variable (raw materials). It's a double-edged sword: high fixed-cost businesses (manufacturing, airlines, software) see profit jump disproportionately as sales grow, but the same fixed costs turn a small sales dip into an outsized loss. That's also why these businesses tend to lead in a bull market and get hit hardest first when demand turns down.
DCF & Graham intrinsic value calculators is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Figures use live Yahoo Finance data where available; any field Yahoo doesn't report falls back to the DeepScreen model.
Loading live headlines…
Review the scoring factors, underlying data and limitations before comparing companies.
Read the methodology